IN THE PAST 30 YEARS, the treatment of acute myelocytic leukemia (AML) has considerably evolved and improved. The general evolution in the therapeutic strategy has invariably been on the direction of more aggressive treatment being administered early, as soon as a first complete remission (CR1) has
No takes yet. Share an insight, caveat, or question.
Norbert Claude Gorin (1998) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: